体外研究 (In Vitro) |
5-O-Methylvisammioside 可有效阻断脂多糖诱导 BV-2 小胶质细胞产生的炎症因子。 5-O-Methylvisammioside (50-500 μg/mL; 24 h) 在浓度高达 500 μg/mL 时对人脐静脉内皮细胞无毒性,并呈剂量依赖性抑制 HMGB1 诱导的人脐静脉内皮细胞增殖。 5-O-Methylvisammioside (100-500 μg/mL; 24 h) 在伤口愈合实验中呈剂量依赖性抑制 HMGB1 诱导的人脐静脉内皮细胞迁移。 5-O-Methylvisammioside (100-500 μg/mL; 24 h) 可在 Transwell 实验中剂量依赖性地抑制 HMGB1 诱导的人脐静脉内皮细胞迁移。 5-O-Methylvisammioside (100-500 μg/mL; 16 h) 可剂量依赖性地抑制 HMGB1 诱导的人脐静脉内皮细胞管形成。 5-O-Methylvisammioside (100-500 μg/mL) 呈剂量依赖性地抑制人脐静脉内皮细胞中由 HMGB1 诱导的 RAGE、磷酸化 MEK 及磷酸化 ERK 的上调表达。 5-O-Methylvisammioside (250 μg/mL) 可抑制 HMGB1 诱导的人脐静脉内皮细胞中 RAGE 的上调。 5-O-Methylvisammioside (100-500 μg/mL) 可剂量依赖性地抑制人脐静脉内皮细胞中由 HMGB1 诱导的 VEGF 生成。 5-O-Methylvisammioside (40 μM; 48 h) 可显著降低经 Erastin (MS-C46386) 处理的 Caco-2 细胞的氧化应激水平、纠正铁代谢紊乱、恢复铁死亡相关蛋白表达量并降低炎性细胞因子水平,且这些保护作用严格依赖 Nrf2/HO-1 通路,因为 Nrf2 敲低可显著削弱上述效应。 5-O-Methylvisammioside (10 μM; 45 min) 可强效抑制过表达 CNT2 的 HEK293 细胞中 CNT2 介导的腺苷摄取,其 IC50 为 11.22 μM,在 10 μM 浓度下的活性强于其他受试化合物。 5-O-Methylvisammioside (10 μM; 24 h) 可抑制经 720 μM 尿酸 (UA) (MS-G49441) 刺激 24 h 后的人肠上皮细胞中 ROS 的生成,这一点可通过 DCFH-DA 荧光强度降低以及 SOD/NOX4 mRNA 表达的调控得到证实。 5-O-Methylvisammioside (10 μM; 24 h) 可抑制 ROS/NF-κB/NLRP3 通路的激活,并恢复经 720 μM UA 刺激 24 h 的人肠上皮细胞中的紧密连接蛋白表达。
Cell Migration Assay
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
100, 250, 500 μg/mL
|
| Incubation Time: |
24 h |
| Result: |
Dose-dependently reduced HMGB1-enhanced wound closure at 100, 250, 500 μg/mL, with significant inhibition observed at all tested concentrations.\n Significantly reduced the number of HMGB1-increased migrated cells at 100, 250, 500 μg/mL, with dose-dependent inhibition observed. |
Western Blot Analysis
| Cell Line: |
UA-stimulated human intestinal epithelial cells (HIEC) |
| Concentration: |
10 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced phosphorylation of NF-κB p65, and decreased protein expression of NLRP3, ASC, and caspase-1 in UA-stimulated HIEC. Increased protein expression of tight junction proteins ZO-1 and Occludin in UA-stimulated HIEC. |
|
体内研究 (In Vivo) |
5-O-methylvisammioside (5-10 mg/kg;腹腔注射;每日 1 次,连续 7 天) 可通过抑制 TNF、MAPK、NF-κB 和花生四烯酸通路,降低血清肝酶及炎症细胞因子水平,改善肝脏组织病理学特征,缓解 Acetaminophen (MS-H20928) 诱导的雄性 ICR 小鼠急性肝损伤。 5-O-Methylvisammioside (12.5-50 mg/kg;每日一次;连续 14 天) 可剂量依赖性抑制 C57BL/6 小鼠原位肝细胞癌的生长,在 50 mg/kg 剂量下的最大肿瘤抑制率达 62.64%,其作用机制为抑制肿瘤血管生成并下调 HMGB1/RAGE/MEK/ERK 信号通路。 5-O-Methylvisammioside (3.5-7 mg/kg/天;腹腔注射;每日一次,连续 14 天) 可呈剂量依赖性缓解 DSS (MS-A45736) 诱导的雄性 Sprague-Dawley 大鼠溃疡性结肠炎。 5-O-Methylvisammioside (5-20 mg/kg;灌胃;单次给药) 可使单次给药的高尿酸血症 (HUA) 小鼠的血清尿酸峰值降低最多 39.1%(10 mg/kg 剂量),并加快尿酸水平恢复至基线。 5-O-Methylvisammioside (5-20 mg/kg;灌胃,每日一次,连续 4 周) 可降低慢性高尿酸血症小鼠的血清尿酸和腺苷水平,改善肝肾功能,缓解肠道炎症与氧化应激,恢复肠道屏障功能,使肠道 CNT2 表达恢复正常。
| Animal Model: |
ICR (male, adult, 20-22 g, acetaminophen-induced acute liver injury) |
| Dosage: |
5 mg/kg; 10 mg/kg |
| Administration: |
i.p.; daily; 7 days |
| Result: |
Significantly reduced serum alanine aminotransferase and aspartate aminotransferase levels compared to the acetaminophen-only group. Significantly reduced liver inflammatory cell infiltration and hepatocyte vacuolation compared to the acetaminophen-only group. Significantly decreased serum TNF-α and IL-1β levels compared to the acetaminophen-only group. Significantly suppressed hepatic mRNA expression of TNF-α, IL-1β, Ptges, p38, and RelB compared to the acetaminophen-only group. Significantly inhibited IκB-α phosphorylation and NF-κB nuclear translocation compared to the acetaminophen-only group. Significantly suppressed phosphorylation of JNK and p38 in the MAPK pathway compared to the acetaminophen-only group, with no significant effect on Erk1/2 phosphorylation. Regulated 4675 differentially expressed hepatic genes compared to the acetaminophen-only group, with enrichment in TNF, MAPK, NF-κB, and arachidonic acid pathways at 10 mg/kg dose. Regulated 249 hepatic metabolites compared to the acetaminophen-only group, including significant reduction in pro-inflammatory prostaglandins (D2, B2, A2) linked to the arachidonic acid pathway at 10 mg/kg dose. |
| Animal Model: |
C57BL/6 (male, 8 weeks old, 20g) |
| Dosage: |
12.5 mg/kg; 25 mg/kg; 50 mg/kg |
| Administration: |
daily; 14 days |
| Result: |
Reduced tumor weight with tumor inhibition rates of 42.24%, 55.48%, and 62.64% for the 12.5 mg/kg, 25 mg/kg, and 50 mg/kg doses, respectively. Decreased CD31 H-scores in tumor tissues across all three doses. Exhibited dose-dependent reductions in HMGB1, RAGE, p-MEK, and p-ERK protein levels compared to the model group. Reduced tumor tissue HMGB1 levels and VEGF levels across all three doses. Caused no significant changes in body weight during the 14-day period. |
| Animal Model: |
Sprague-Dawley (male, 6 weeks old, 200 g, specific pathogen-free, ulcerative colitis induced by 3% dextran sulfate sodium) |
| Dosage: |
3.5 mg/kg/day; 7 mg/kg/day |
| Administration: |
i.p.; daily; 14 days |
| Result: |
Reduced disease activity index scores compared to the DSS model group, with the high dose showing greater efficacy. Significantly increased colon length, reduced colon damage index scores, lowered spleen index, and increased thymus index. Partially ameliorated mucosal ulceration, crypt atrophy, and inflammatory infiltration at low dose; showed improved gland/crypt organization and reduced inflammation, with near-normal mucosa similar to mesalazine at high dose. Reduced colon tissue levels of IL-6, IL-8, and TNF-α. Restored goblet cell numbers, upregulated protein and mRNA levels of tight junction proteins occludin and ZO-1. Reduced oxidative stress markers MDA, 4-HNE, and MPO activity, and increased GSH content. Reduced total iron content, upregulated FTH1 expression, and downregulated Tfrc and Slc11a2 levels to restore iron homeostasis. Improved mitochondrial morphology (reduced swelling, increased cristae organization) compared to the DSS group, with high-dose rats showing discernible mitochondrial double membranes. Upregulated protein and mRNA levels of ferroptosis markers GPX4 and SLC7A11, and downregulated ACSL4. Dose-dependently upregulated protein and mRNA levels of Nrf2 and HO-1, with high-dose levels exceeding normal control levels. |
| Animal Model: |
C57BL/6J (6-week-old, SPF-grade, male, hyperuricemia induced by daily intraperitoneal injection of potassium oxonate plus intragastric gavage of yeast paste for single-dose study) |
| Dosage: |
5 mg/kg; 10 mg/kg; 20 mg/kg |
| Administration: |
i.g.; single dose |
| Result: |
Reduced peak serum uric acid levels to 194.44 μM (5 mg/kg), 174.76 μM (10 mg/kg), 176.93 μM (20 mg/kg). Lowered peak serum uric acid levels by up to 39.1% (10 mg/kg dose). Accelerated serum uric acid return to pre-dose levels by 4 h post-treatment. |
| Animal Model: |
C57BL/6J (6-week-old, SPF-grade, male, hyperuricemia induced by daily intraperitoneal injection of potassium oxonate plus intragastric gavage of yeast paste for 4 weeks) |
| Dosage: |
5 mg/kg; 10 mg/kg; 20 mg/kg |
| Administration: |
i.g.; daily; 4 weeks |
| Result: |
Significantly reduced serum uric acid levels in all treated groups, with the 10 mg/kg dose showing the greatest reduction. Significantly decreased serum and urine adenosine levels; 5 and 10 mg/kg doses showed better inhibitory effects on adenosine absorption than positive control drugs. Significantly reduced elevated CNT2 protein expression in the duodenum, jejunum, and ileum induced by HUA. Ameliorated liver pathology (bile duct hyperplasia, inflammatory cell infiltration, steatosis) and kidney pathology (renal tubular epithelial cell edema, tubular/corpuscle dilation, inflammatory cell infiltration), and reduced serum ALT, AST, and Cr levels compared to the model group. Significantly decreased serum and intestinal levels of inflammatory factors (IL-1β, IL-6, TNF-α) and oxidative stress marker MDA, while increased serum SOD levels compared to the model group. Reduced intestinal permeability (measured via FITC-dextran), and restored intestinal tight junction protein expression (ZO-1, Occludin) in the duodenum, jejunum, and ileum compared to the model group. Improved intestinal histopathology (epithelial detachment, shortened/sparse villi, inflammatory cell infiltration) and preserved villi structure. |
|